http://orcid.org/0000-0001-7008-4770
References
- World Health Organization. Background document: the diagnosis, treatment and prevention of typhoid fever. 2003.
- Wain J, Hendriksen RS, Mikoleit ML, et al. Typhoid fever. Lancet. 2015;385:1136–1145.
- Tilahun GT, Makinde OD, Malonza D. Modelling and optimal control of typhoid fever disease with cost-effective strategies. Comput Math Methods Med. 2017;1–16. Article ID 2324518.
- Felgner J, Jain A, Nakajima R, et al. Development of ELISAs for diagnosis of acute typhoid in Nigerian children. PLoS Negl Trop Dis. 2017;11(6):e0005679.
- Howick J, Cals JW, Jones C, et al. Current and future use of point-of-care tests in primary care: an international survey in Australia, Belgium, The Netherlands, the UK and the USA. BMJ Open. 2014 Aug 1;4(8):e005611.
- Tyndall A, Wenny D, Breder CD. Regulatory watch: the target product profile as a tool for regulatory communication: advantageous but underused. Nat Rev Drug Discov. 2017 Mar;16(3):156.
- Trikalinos TA, Siebert U, Lau J. Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations. Med Decis Making. 2009 Sep;29(5):E22–9.
- Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006 Dec 1;15:(12)1295–1310.
- Keeling MJ, Rohani P. Modeling infectious diseases in humans and animals. Oxfordshire: Princeton University Press; 2011 Sep 19.
- Watson CH, Edmunds WJ. A review of typhoid fever transmission dynamic models and economic evaluations of vaccination. Vaccine. 2015 Jun 19;33:C42–54.
- Meltzer E, Sadik C, Schwartz E. Enteric fever in Israeli travelers: a nationwide study. J Travel Med. 2005 Sep 1;12(5):275–281.
- Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment. Pharmacoeconomics. 2006 Apr 1;24(4):355–371.
- Canh DG, Whittington D, Thoa LT, et al. Household demand for typhoid fever vaccines in Hue, Vietnam. Health Policy Plan. 2006 Mar 30;21(3):241–255.
- Shepard DS, Walsh JA, Kleinau E, et al. Setting priorities for the Children’s Vaccine Initiative: a cost-effectiveness approach. Vaccine. 1995 Jan 1;13(8):707–714.
- Musgrove P. Cost-benefit analysis of a regional system for vaccination against pneumonia, meningitis type B, and typhoid fever. Bull PAHO. 1992;26:173–191.
- Lauria DT, Maskery B, Poulos C, et al. An optimization model for reducing typhoid cases in developing countries without increasing public spending. Vaccine. 2009 Mar 4;27(10):1609–1621.
- Poulos C, Bahl R, Whittington D, et al. A cost-benefit analysis of typhoid fever immunization programmes in an Indian urban slum community. J Health, Popul Nutr. 2004 Sep;22:311–321.
- Cook J, Jeuland M, Whittington D, et al. DOMI typhoid economics study group. the cost-effectiveness of typhoid vi vaccination programs: calculations for four urban sites in four asian countries. Vaccine. 2008 Nov 25;26(50):6305–6316.
- Cook J, Sur D, Clemens J, et al. Evaluating investments in typhoid vaccines in two slums in Kolkata, India. J Health Popul Nutr. 2009 Dec;27(6):711.
- Drake TL, Devine A, Yeung S, et al. Dynamic transmission economic evaluation of infectious disease interventions in low- and middle-income countries: a systematic literature review. Health Econ. 2016 Feb 1;25 Suppl 1:(S1)124–139.
- Tawiah T, Hansen KS, Baiden F, et al. Cost-effectiveness analysis of test-based versus presumptive treatment of uncomplicated malaria in children under five years in an area of high transmission in central Ghana. PLoS One. 2016 Oct 3;11(10):e0164055.
- Hansen KS, Ndyomugyenyi R, Magnussen P, et al. Cost-effectiveness analysis of malaria rapid diagnostic tests for appropriate treatment of malaria at the community level in Uganda. Health Policy Plan. 2017 Jun 1;32(5):676–689.
- Lo NC, Gupta R, Stanaway JD, et al. Comparison of strategies and incidence thresholds for vi conjugate vaccines against typhoid fever: a cost-effectiveness modeling study. J Infect Dis. 2018 Feb 12;jix598. doi:10.1093/infdis/jix598.